These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 19098393

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cancer biomarkers: current issues and future directions.
    Jain KK.
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X, Wang Z.
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New approaches to molecular cancer therapeutics.
    Collins I, Workman P.
    Nat Chem Biol; 2006 Dec; 2(12):689-700. PubMed ID: 17108987
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Somatic pharmacogenomics in cancer.
    Ikediobi ON.
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH.
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS.
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [Abstract] [Full Text] [Related]

  • 18. Predictive medicine: incipient reality or fata morgana?
    Dietel M.
    J Pathol; 2007 Aug; 212(4):353-5. PubMed ID: 17573671
    [Abstract] [Full Text] [Related]

  • 19. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy.
    Zhang E, Zhang C, Su Y, Cheng T, Shi C.
    Drug Discov Today; 2011 Feb; 16(3-4):140-6. PubMed ID: 21182981
    [Abstract] [Full Text] [Related]

  • 20. Challenges of drug discovery for personalized medicine.
    Jain KK.
    Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.